Paratek Pharmaceuticals Inc is a United Stakes-based commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its commercial product, NUZYRA (omadacycline), is a once-daily oral and intravenous antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia (CABP), and acute skin and skin structure infections (ABSSSI) caused by susceptible pathogens.
Its other commercial product SEYSARA (sarecycline), is a once-daily oral therapy for the treatment of moderate to severe acne vulgaris. The Sarecycline is a narrow spectrum tetracycline designed specifically for dermatological use..
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 1.7M |
| Three Month Average Volume | 13.8M |
| High Low | |
| Fifty-Two Week High | 3.65 USD |
| Fifty-Two Week Low | 1.29 USD |
| Fifty-Two Week High Date | 01 Nov 2022 |
| Fifty-Two Week Low Date | 16 Mar 2023 |
| Price and Volume | |
| Current Price | 2.23 USD |
| Beta | 2 |
| Relative Price Change | |
| Four Week Relative Price Change | 3.08% |
| Thirteen Week Relative Price Change | 0.07% |
| Twenty-Six Week Relative Price Change | 10.49% |
| Fifty-Two Week Relative Price Change | -18.61% |
| Year-to-Date Relative Price Change | 4.01% |
| Price Change | |
| One Day Price Change | 1.83% |
| Thirteen Week Price Change | 0.90% |
| Twenty-Six Week Price Change | 23.55% |
| Five Day Price Change | 1.36% |
| Fifty-Two Week Price Change | -7.08% |
| Year-to-Date Price Change | 19.25% |
| Month-to-Date Price Change | 0.90% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | -3.01919 USD |
| Book Value Per Share (Most Recent Quarter) | -3.51531 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | -3.03383 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | -3.52979 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -0.78606 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 2.94676 USD |
| Revenue Per Share (Trailing Twelve Months) | 3.1452 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -1.16875 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -1.11491 USD |
| Normalized (Last Fiscal Year) | -1.16875 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -1.16875 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -1.11491 USD |
| Including Extraordinary Items (Last Fiscal Year) | -1.16875 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -1.11491 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 0.60454 USD |
| Cash Per Share (Most Recent Quarter) | 0.74517 USD |
| Cash Flow Per Share (Last Fiscal Year) | -1.15974 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -1.10927 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -0.41314 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -117 |
| Cash Flow Revenue (Trailing Twelve Months) | -13 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -35.35% |
| Pretax Margin (Last Fiscal Year) | -39.63% |
| Pretax Margin (5 Year) | -123.68% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | 85.61% |
| Gross Margin (Trailing Twelve Months) | 85.71% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -28.83% |
| Operating Margin (Trailing Twelve Months) | -25.17% |
| Operating Margin (5 Year) | -103.75% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -39.66% |
| Net Profit Margin (Trailing Twelve Months) | -35.44% |
| Net Profit Margin (5 Year) | -124.08% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -99,999.99% |
| Tangible Book Value (5 Year) | -99,999.99% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | 34.94% |
| Revenue Growth (3 Year) | 66.26% |
| Revenue Change (Trailing Twelve Months) | 59.83% |
| Revenue Per Share Growth | 44.34% |
| Revenue Growth (5 Year) | 113.17% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -49.69% |
| Total Debt (5 Year) | 34.10% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 23.54% |
| EPS Change (Trailing Twelve Months) | 33.74% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | -100,000 |
| Price to Tangible Book (Most Recent Quarter) | -100,000 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | 215.6M |
| Net Debt (Last Fiscal Year) | 222.7M |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 1 |
| Price to Sales (Trailing Twelve Months) | 1 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | -100,000 |
| Price to Book (Most Recent Quarter) | -100,000 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | -100,000 |
| Long Term Debt to Equity (Most Recent Quarter) | -100,000 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | 3 |
| Quick Ratio (Most Recent Quarter) | 0 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 4 |
| Current Ratio (Most Recent Quarter) | 1 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -66,177,000 |
| Free Cash Flow (Trailing Twelve Months) | -23,250,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -3 |
| Net Interest Coverage (Trailing Twelve Months) | -2 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | -100,000 |
| Total Debt to Equity (Most Recent Quarter) | -100,000 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -35.67% |
| Return on Assets (Trailing Twelve Months) | -40.54% |
| Return on Assets (5 Year) | -42.62% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -99,999.99% |
| Return on Equity (Trailing Twelve Months) | -99,999.99% |
| Return on Equity (5 Year) | -99,999.99% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -44.19% |
| Return on Investment (Trailing Twelve Months) | -163.44% |
| Return on Investment (5 Year) | -48.16% |